Preclinical evaluation of coronary stents: focus on safety issues.
In recent years, we have witnessed a revolution in the treatment of coronary artery disease. The development and improvement of drug eluting stents (DES) have lowered the incidence of restenosis to one-digit figures. In the search for a superior efficacy, animal models have played a key role. The classical swine model of coronary stenting remains the preferred model to measure restenosis, although the rabbit iliac artery stenting has become an accepted alternative. After widespread clinical use of DES, an unforeseen complication arose: late stent thrombosis. In a back-to-bench step, some data from animal models helped to explain the phenomenon. A delayed and incomplete vascular healing was detected. Toxic and hypersensitivity reactions to polymers and/or drugs seem to be the underlying causes. So, translational research focused on the safety aspect of these devices: development of better drug carriers as absorbable polymers or fully bioresorbable scaffolds, selection of different drugs and assessment of the re-endothelialization process. We review and evaluate the efficacy and safety of coronary stents in different animal models. Further improvements in this field such as, the selection of better animal models (e.g. hyperlipidemic, diabetic, atherosclerotic) that closely mimic the clinical setting and longer follow-up periods to detect late complications are also discussed.
Fundación Investigación Sanitaria en León, Grupo Cardiovascular and Instituto de Biomedicina (IBIOMED), León, Spain. aperez@secardiologia.es
Armando Perez
AP
de Prado
Claudia
C
Perez-Martinez
Carlos
C
Cuellas
Jose M
JM
Gonzalo-Orden
Alejandro
A
Diego
Marta
M
Regueiro
Beatriz
B
Martinez-Fernandez
Jose R
JR
Altonaga
J G
JG
Marin Francisco
Felipe
F
Fernandez-Vazquez
D000818:Animals; D003324:Coronary Artery Disease / Q000188:drug therapy*; D004353:Drug Evaluation, Preclinical; D006801:Humans; D015607:Stents / Q000009:adverse effects*